Clinical Trial Update: An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies [Phase 3]

View source ↗

Summary

Open-label, extended-use Phase 3 trial update of XERECEPT (hCRF) in patients from studies NTI 0302/0303 or other designated studies; the trial is completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Edema
• Brain Tumor

Drugs mentioned

• XERECEPT (human corticotropin-releasing factor)

Snippet

Sponsor: Celtic Pharma Development Services | Conditions: Brain Edema, Brain Tumor | Phase 3 | Status: COMPLETED | Results posted: 2012-08-31